N/A
Loading page data
Please wait a moment
Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500
Hypertrophic cardiomyopathy is a common inherited heart disease with serious adverse outcomes such as arrhythmias, sudden cardiac death and heart failure. Hypertrophic cardiomyopathy is caused due to the mutation or changes in one or more genes, which is inherited. Further, chest pain, fainting & light headaches, and palpitations, are some of the major symptoms of hypertrophic cardiomyopathy.
Further, Hypertrophic cardiomyopathy enabled the development of mouse models that reiterate clinical manifestations of disease. In addition, these models provide unforeseen insight into the chemical and biological properties and which may help to improve clinical diagnosis and management of patient with Hypertrophic cardiomyopathy therapeutics.
According to American Heart Association (AHA), in March 2016, hypertrophic cardiomyopathy affects around 500,000 people in the U.S. annually. Increasing prevalence of chronic cardiovascular diseases which is expected to increase the growth of hypertrophic cardiomyopathy therapeutics market.
In addition, there are various invasive therapy such as septal reduction therapy and heart transplantation which are used against symptomatic patients and this is anticipated to boost the growth of hypertrophic cardiomyopathy therapeutics.
Further, according to the FDA, only propranolol carries an on-label indication for hypertrophic cardiomyopathy but on the other hand, there are some drugs in clinical pipelines such as mavacamten, to be used in obstructive hypertrophic, symptomatic, cardiomyopathy and this is anticipated to increase the demand for hypertrophic cardiomyopathy therapeutics in near future.
Furthermore, market is expected to gain significant growth from government interventions and spreading awareness about hypertrophic cardiomyopathy.However, due to increase in the technological upgradation in devices such as defibrillators and pacemakers are anticipated to hamper the growth of hypertrophic cardiomyopathy therapeutics market.
Rapid increase in corona virus all around the world is expected to hamper the growth of hypertrophic cardiomyopathy therapeutics market.The virus outburst has become one of the threats to the global economy and financial markets.
The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector.
It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of hypertrophic cardiomyopathy therapeutics market.
Some of the major key players competing in the global hypertrophic cardiomyopathy therapeutics market are Pfizer, Inc., Merck & Co Company, Sanofi S.A., Mylan N. V. Teva Pharmaceuticals Limited and others.
